Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739931 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
A Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT03739931 is a Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma that has completed, run by ModernaTX. The registered enrollment target is 134 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT03739931, a Phase 1 study of Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL mRNA-2752
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Cancer Center at Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- NYU Langone Medical Center - New York
- Icahn School of Medicine at Mount Sinai - New York
- James P. Wilmot Cancer Center - Rochester
Other
- Alfred Health - Melbourne
- Westmead Hospital - Westmead
- Melanoma Institute of Australia - Wollstonecraft
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Providence St. John's Health Center - Santa Monica
Colorado
- University of Colorado Denver - Aurora
Connecticut
- Yale Cancer Center - New Haven
Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists - Sarasota
Illinois
- The University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739931
The ClinicalTrials.gov registry entry for NCT03739931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT03739931 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, New York, Other.
Frequently Asked Questions
What is clinical trial NCT03739931 about?
NCT03739931 is a clinical study titled "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies". The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
What is the current status of trial NCT03739931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2018-11-27. Estimated completion is 2025-08-01.
What conditions does trial NCT03739931 study?
This clinical trial studies the following conditions: Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma.
What interventions are being tested in trial NCT03739931?
The interventions under investigation include: Durvalumab (BIOLOGICAL), mRNA-2752 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03739931?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739931 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
All registered trials for this condition
Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.